Hubbry Logo
logo
AM-2201 avatar
AM-2201
Community hub

AM-2201

logo
0 subscribers
Read side by side
AM-2201
View on Wikipedia
from Wikipedia
AM-2201
Legal status
Legal status
Identifiers
  • 1-[(5-Fluoropentyl)-1H-indol-3-yl]-(naphthalen-1-yl)methanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H22FNO
Molar mass359.444 g·mol−1
3D model (JSmol)
  • O=C(C1=CN(CCCCCF)C2=C1C=CC=C2)C3=CC=CC4=C3C=CC=C4
  • InChI=1S/C24H22FNO/c25-15-6-1-7-16-26-17-22(20-12-4-5-14-23(20)26)24(27)21-13-8-10-18-9-2-3-11-19(18)21/h2-5,8-14,17H,1,6-7,15-16H2 checkY
  • Key:ALQFAGFPQCBPED-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor.[3] It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University.

Hazards

[edit]

Convulsions have been reported[4] including at doses as low as 10 mg.[5]

Pharmacology

[edit]

AM-2201 is a full agonist for cannabinoid receptors. Affinities are: with a Ki of 1.0 nM at CB1 and 2.6 nM at CB2.[6] The 4-methyl functional analog MAM-2201 probably has similar affinities.[original research?] AM-2201 has an EC50 of 38 nM for human CB1 receptors, and 58 nM for human CB2 receptors.[7] AM-2201 produces bradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, comparable to the potency of JWH-018 in rats, suggesting potent cannabinoid-like activity.[7]

Pharmacokinetics

[edit]
See also: JWH-018 § Pharmacokinetics

AM-2201 metabolism differs only slightly from that of JWH-018. AM-2201 N-dealkylation produces fluoropentane instead of pentane (or plain alkanes in general).[citation needed]

Detection

[edit]

A forensic standard of AM-2201 is available, and the compound has been posted on the Forendex website of potential drugs of abuse.[8]

[edit]

In the United States, AM-2201 is a Schedule I controlled substance.[9]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

AM-2201

View on Grokipedia
from Grokipedia
AM-2201 (1-(5-fluoropentyl)-1H-indol-3-ylmethanone; C24H22FNO) is a synthetic cannabinoid of the naphthoylindole class that acts as a potent full agonist at the cannabinoid receptors CB1 and CB2, exhibiting particularly high affinity for CB1 (Ki ≈ 1.0 nM).[1][2] Originally synthesized as part of the AM series of compounds by researcher Alexandros Makriyannis for investigating the endocannabinoid system, it features a terminal fluorine substitution on the pentyl chain of JWH-018, enhancing its binding potency.[3][4] Developed in the early 2000s as a research tool to probe receptor interactions rather than for therapeutic use, AM-2201 gained notoriety after its detection in commercial herbal products marketed as "Spice" or synthetic cannabis alternatives around 2009–2010, where it was sprayed onto plant material for smoking.[5][6] These products evaded initial drug laws by mimicking natural cannabis effects while being chemically distinct, leading to widespread recreational abuse despite lacking standardization in dosing or purity.[7] Pharmacologically, AM-2201 induces hypothermia, catalepsy, and analgesic effects in animal models at doses far lower than those of Δ9-tetrahydrocannabinol (THC), reflecting its greater efficacy and lipophilicity, which prolongs its duration of action up to several hours.[3] Human case reports document acute adverse effects including tachycardia, psychosis, seizures, and agitation, often more severe than those from natural cannabis due to its full agonism and potential for unexpected potency in unregulated formulations.[6][8] In response to public health risks from such intoxications, AM-2201 was temporarily placed into Schedule I of the U.S. Controlled Substances Act in 2014 and remains classified as a Schedule I substance, denoting high abuse potential and no accepted medical use.[7][9] Similar bans followed internationally, underscoring concerns over its role in emergency department visits and fatalities linked to synthetic cannabinoid variability.[5]

Chemistry

Chemical Structure and Properties

AM-2201, chemically known as 1-(5-fluoropentyl)-1H-indol-3-ylmethanone, features an indole ring core substituted at the 3-position with a 1-naphthoyl moiety and at the 1-position (nitrogen) with a 5-fluoropentyl alkyl chain.[1] This structure places it within the naphthoylindole class of synthetic cannabinoids, characterized by the naphthoyl group as the key pharmacophore interacting with cannabinoid receptors.[2] The molecular formula is C24H22FNO, with a molecular weight of 359.44 g/mol.[10] Physicochemical properties include a melting point of 93.7 °C, indicating a solid state at room temperature.[11] The compound exhibits high lipophilicity, reflected in a computed XLogP3 value of 6.92, which facilitates its partitioning into biological membranes.[2] It possesses no hydrogen bond donors and a topological polar surface area of 22 Ų, contributing to its low polarity and potential for rapid absorption.[2] The boiling point remains undetermined due to likely thermal decomposition.[12]

Synthesis Methods

The synthesis of AM-2201, chemically known as 1-(5-fluoropentyl)-3-(1-naphthoyl)indole, was first reported in 2001 by Alexandros Makriyannis and Hongfeng Deng as part of a series of cannabimimetic indole derivatives. The process begins with the acylation of indole at the 3-position to form 1H-indol-3-yl(naphthalen-1-yl)methanone. This involves dissolving indole in ethyl acetate, adding methylmagnesium bromide (as a promoter for regioselective C3 acylation), and then introducing 1-naphthoyl chloride—prepared from 1-naphthalenecarboxylic acid and thionyl chloride. The reaction mixture is quenched with aqueous ammonium chloride, filtered, washed, and recrystallized to isolate the intermediate. N-alkylation follows by treating the 3-acylated indole with sodium hydride in dimethylformamide (DMF), followed by addition of 5-bromopentyl acetate to attach the protected pentyl chain at the indole nitrogen. The acetate protecting group is then removed via hydrolysis with methanolic potassium hydroxide, yielding the corresponding 5-hydroxypentyl intermediate. Fluorination of the terminal hydroxyl to introduce the 5-fluoro group is achieved using diethylaminosulfur trifluoride (DAST) in dichloromethane, affording AM-2201 after purification. This multi-step route leverages standard organometallic and nucleophilic substitution chemistry typical for naphthoylindole cannabinoids, with yields dependent on purification steps such as recrystallization and chromatography. Alternative sequences, such as initial N-alkylation of indole followed by C3 acylation, have been employed for analogous compounds but were not detailed for AM-2201 in the original disclosure. Illicit production, often reported in forensic analyses, mirrors this lab method but may employ less pure reagents and omit rigorous purification, potentially leading to impurities like JWH-018 or JWH-022 as byproducts under thermal stress.[13]

History

Development as a Research Tool

AM-2201, chemically known as 1-(5-fluoropentyl)-3-(1-naphthoyl)indole, was first synthesized in 2001 by Alexandros Makriyannis and Hongfeng Deng at Northeastern University as part of the AM series of aminoalkylindole cannabinoids designed to serve as selective ligands for studying the endocannabinoid system.[11] These compounds were developed to explore structure-activity relationships at cannabinoid receptors, building on earlier efforts to create analogs of Δ9-tetrahydrocannabinol (THC) with enhanced potency and receptor affinity for preclinical pharmacological research.[14] The synthesis involved starting from 1-H indole, followed by alkylation with 1-bromo-5-fluoropentane to introduce the fluoropentyl side chain at the indole nitrogen, and subsequent acylation with 1-naphthoyl chloride at the 3-position, yielding a molecule optimized for high-affinity binding to CB1 receptors (Ki = 1.0 nM) while showing lower affinity for CB2 (Ki = 24 nM).[11][14] This structural modification, particularly the fluorine substitution, was intended to enhance metabolic stability and receptor interaction compared to non-fluorinated analogs like JWH-018, facilitating detailed binding and functional assays in vitro and in vivo.[15] As a research tool, AM-2201 enabled investigations into CB1-mediated signal transduction, including G-protein coupling and downstream effects such as hypothermia, catalepsy, and antinociception in rodent models, with dose-dependent responses peaking at 2 hours post-administration and persisting up to 8 hours.[16] It was employed in drug discrimination studies to assess THC-like subjective effects, confirming its full agonist profile at CB1 receptors and utility in modeling cannabinoid dependence and tolerance mechanisms.[17] Early studies highlighted its role in elucidating receptor desensitization and internalization, providing insights into potential therapeutic applications for pain and neurological disorders before its identification in recreational products around 2010.[18]

Emergence in Recreational Markets

AM-2201 entered recreational markets primarily as an active ingredient in synthetic cannabinoid-infused herbal products marketed under brands like Spice and K2, positioned as legal alternatives to natural cannabis despite warnings of "not for human consumption."[19] These products gained traction amid a wave of novel psychoactive substances following bans on earlier synthetic cannabinoids such as JWH-018, which was temporarily scheduled in the United States in March 2011.[20] In Europe, AM-2201 was first reported to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in January 2011 by Latvian authorities, with subsequent detections in Poland by December 2011.[21][22] By mid-2011, AM-2201 had proliferated in post-ban herbal mixtures, comprising up to 70% of analyzed products in some surveys of legal highs, as manufacturers substituted it for controlled precursors to evade regulations.[23] Its emergence aligned with a broader shift to second-generation synthetic cannabinoids, including fluorinated analogs like AM-2201, which offered similar CB1 receptor agonism but evaded initial analog controls.[24] Sold online and in head shops as potpourri or incense, these mixtures appealed to users seeking cannabis-like euphoria, relaxation, and perceptual alterations at doses as low as 0.25–3 mg when smoked.[25] The compound's rapid dissemination led to detections across 27 countries by December 2013, often linked to acute intoxications including psychosis, convulsions, and fatalities, prompting expanded monitoring and scheduling efforts.[26] In the U.S., forensic reports confirmed its role in driving-related cases and overdose clusters by 2012, underscoring its potency relative to natural THC and the risks of unregulated dosing in recreational contexts.[27] Despite these hazards, its availability persisted until broader synthetic cannabinoid bans, such as the U.S. temporary placement into Schedule I in January 2014 alongside AM-2201 specifically.[7]

Pharmacology

Mechanism of Action

AM-2201 functions as a potent, nonselective full agonist at the G-protein-coupled cannabinoid receptors CB1 and CB2, mimicking the effects of endogenous cannabinoids such as anandamide by binding to these receptors and activating downstream signaling pathways, including inhibition of adenylyl cyclase and modulation of ion channels.[28] This agonism primarily occurs at CB1 receptors in the central nervous system, which mediate psychoactive effects, while CB2 activation influences peripheral immune responses.[25] The compound's 5-fluoropentyl side chain enhances its binding affinity compared to non-fluorinated analogs like JWH-018, contributing to greater potency.[29] Binding affinity studies report a Ki value of 1.0 nM at CB1 and 2.6 nM at CB2, indicating high potency and approximately 40-fold greater CB1 affinity than Δ9-tetrahydrocannabinol (THC).[28][25] As a full agonist, AM-2201 elicits maximal receptor activation, leading to pronounced cannabimimetic effects such as hypothermia, catalepsy, and altered sensory perception in preclinical models, without the partial agonism characteristic of THC.[3] This profile underscores its nonselective nature, potentially amplifying off-target effects relative to more selective natural cannabinoids.[30]

Physiological and Behavioral Effects

In preclinical studies using male rats, subcutaneous administration of AM-2201 at doses of 0.1–1.0 mg/kg induced dose-dependent hypothermia, with temperature decreases of 1.4–4.0°C peaking at 2 hours post-injection and persisting up to 8 hours.[18] The compound also elicited catalepsy, characterized by immobility, flattened body posture, and splayed limbs, peaking at 1 hour and lasting up to 4 hours at the same doses.[18] In mice, AM-2201 triggered seizures mediated by CB1 receptor activation and enhanced hippocampal glutamatergic transmission, manifesting as rigid posture, tail extension, rearing, jumping, and tonic-clonic jerks accompanied by electroencephalographic spike-wave discharges.[31] Human intoxication reports link AM-2201 to severe psychiatric effects, including acute psychosis and extreme agitation, as evidenced by a fatal case involving a 23-year-old male with blood concentrations of 12 ng/mL AM-2201, where symptoms progressed to self-inflicted stabbing wounds amid room disarray suggestive of hallucinatory or delusional states.[6] Physiological manifestations in such cases include potential tachycardia and seizures, consistent with broader synthetic cannabinoid toxicities, though direct attribution to AM-2201 requires confirmation via toxicology, as co-exposure to other agents like JWH-018 metabolites was present.[6] Low-dose oral administration (5 mg) in controlled settings has occasionally produced no discernible psychological or physiological effects, highlighting dose- and route-dependent variability, with smoked or higher exposures more likely to yield adverse outcomes.[14] Behaviorally, AM-2201 substitutes for Δ9-tetrahydrocannabinol (THC) in discrimination assays, indicating THC-like subjective effects such as altered perception, but with amplified risks of panic, vomiting, and convulsions at doses exceeding 10 mg based on user reports corroborated by toxicological analyses.[17][28] These effects stem from its high-affinity full agonism at CB1 receptors, surpassing THC's potency and predisposing to dissociative or stimulant-like states akin to phencyclidine rather than mild cannabis intoxication.[6]

Pharmacokinetics

Absorption and Distribution

AM-2201, a highly lipophilic synthetic cannabinoid receptor agonist, is predominantly consumed recreationally through inhalation by smoking or vaporizing herbal mixtures sprayed with the compound, facilitating rapid pulmonary absorption into the systemic circulation similar to other smoked cannabinoids.[26][22] In rodent models using subcutaneous administration (0.1–1.0 mg/kg), absorption is prompt, with plasma concentrations rising linearly with dose and reaching maximum levels (Cmax) of 8.2–42 µg/L at approximately 1.3 hours post-injection, remaining detectable up to 24 hours at higher doses.[18] Oral bioavailability appears limited, potentially due to gastric degradation, poor gastrointestinal uptake, or extensive first-pass metabolism, as evidenced by reduced pharmacodynamic effects compared to parenteral routes in rats.[18] Distribution of AM-2201 is influenced by its moderate-to-high lipophilicity (log D7.4 values typical for synthetic cannabinoid receptor agonists ranging 2.48–4.95) and strong plasma protein binding, promoting extensive tissue penetration including the brain to elicit central nervous system effects via CB1 receptor agonism.[32] In rat plasma pharmacokinetic studies, parent AM-2201 predominates over metabolites (e.g., JWH-018 N-(5-hydroxypentyl) and N-pentanoic acid at <1 µg/L), suggesting minimal redistribution via active metabolites and half-lives of 4.3–6.3 hours for the parent compound.[18][25] Human data on volume of distribution or specific tissue partitioning remain scarce, though the compound's structural analogy to JWH-018 implies adipose sequestration and prolonged elimination consistent with lipophilic cannabinoids.[18]

Metabolism and Elimination

AM-2201 undergoes extensive hepatic metabolism primarily via cytochrome P450 enzymes, including CYP2D6, resulting in oxidative transformations such as hydroxylation of the alkyl side chain, defluorination, and further oxidation to carboxylic acids.[33] In human urine samples from users, major metabolites include JWH-018 N-(5-hydroxypentyl), JWH-018 N-pentanoic acid (arising from defluorination and subsequent oxidation), AM-2201 N-(4-hydroxypentyl), and AM-2201 6-hydroxyindole, with additional monohydroxylated and carboxylated species on the naphthoyl and indole rings.[34] [35] These metabolites often undergo glucuronidation, facilitating their detection as biomarkers in biological fluids.[25] In rat pharmacokinetic studies following subcutaneous administration (0.3–3 mg/kg), plasma concentrations of parent AM-2201 peak at approximately 1.3 hours post-dose, with detectable levels of the metabolites AM-2201 N-(4-hydroxypentyl), JWH-018 N-(5-hydroxypentyl), and JWH-018 N-pentanoic acid appearing later (T_max ~2.4–6.5 hours).[18] The elimination half-life of AM-2201 in rats is dose-dependent, ranging from 4.3 to 6.3 hours, with area under the curve (AUC) values of 51–487 h·µg/L for the parent compound and lower for metabolites (0.71–12 h·µg/L), indicating rapid clearance primarily through metabolism rather than unchanged excretion.[18] Human data on elimination kinetics remain limited, but urinary metabolite profiles suggest predominant renal clearance of phase II conjugates, consistent with patterns observed for related synthetic cannabinoids.[36] No significant biliary or fecal elimination pathways have been reported for AM-2201.[34]

Toxicology and Adverse Effects

Acute Toxicity Incidents

In 2013, a fatal case was reported involving psychiatric complications after exposure to AM-2201 present in K2 herbal incense. A young adult male developed extreme agitation, hallucinations, paranoia, and combative behavior following inhalation, leading to self-injurious actions and death despite medical intervention; postmortem toxicology confirmed AM-2201 as the primary substance detected, with no other significant contributors identified. Four non-fatal acute intoxication cases involving AM-2201 were documented in 2013, presenting with symptoms such as agitation, tachycardia, hypertension, mydriasis, nausea, vomiting, confusion, dizziness, anxiety, palpitations, and hallucinations. Blood concentrations ranged from 1.2 to 8.6 ng/mL, confirmed via LC-MS/MS; all individuals recovered with supportive treatments including benzodiazepines and fluids, highlighting the substance's role in eliciting sympathomimetic and psychotomimetic effects.[37] A 2017 forensic case illustrated AM-2201's potential for severe behavioral disruption, where an 18-year-old male with a blood concentration of 0.48 ng/mL after consuming "Mr Green – No Bad Trip" (containing 4.85% AM-2201) exhibited panic, impaired volition, and perpetrated a stabbing homicide, claiming diminished awareness; analysis via GC-MS and LC-MS/MS corroborated the intoxication's contribution to the acute episode.[8] Additional isolated reports include a 2012 intoxication of a young female with AM-2201 combined with JWH-210 after smoking an herbal blend, though detailed symptoms and outcomes were not fully elaborated beyond confirming exposure.[38] These incidents underscore AM-2201's higher potency relative to natural cannabinoids, often resulting in unpredictable cardiovascular, neurological, and psychiatric toxicity at low doses.[6]

Long-Term Risks and Comparisons to Natural Cannabinoids

Limited data exist on the long-term risks of AM-2201 due to its relatively recent emergence and illicit use patterns, but chronic exposure to synthetic cannabinoids including this compound has been linked to persistent psychosis, a severe outcome not typically observed with natural cannabinoid use.[39] In a cohort study of individuals with at least two years of synthetic cannabinoid use, participants exhibited significant impairments in executive functions such as decision-making and impulse control, alongside elevated rates of mood disorders including depression and anxiety.[40] Case reports document ongoing cognitive dysfunction, including memory deficits and reduced attention, persisting beyond acute intoxication phases.[26] Immunosuppressive effects have also been noted in human observations, potentially increasing vulnerability to infections over extended use.[26] Cardiovascular strain from repeated tachycardia and hypotension may contribute to long-term organ damage, with synthetic cannabinoids demonstrating prolonged receptor binding compared to natural analogs, exacerbating cumulative toxicity.[41] Dependence develops rapidly due to AM-2201's high efficacy at CB1 receptors, leading to withdrawal syndromes involving irritability, insomnia, and cravings more intense than those from Δ9-tetrahydrocannabinol (THC).[42] Fatal psychiatric complications, such as suicidal ideation or catatonia, have been reported in cases of prolonged exposure, highlighting risks of irreversible mental health deterioration.[6] In comparison to natural cannabinoids like THC, AM-2201 poses elevated risks owing to its full agonism at CB1 receptors versus THC's partial agonism, resulting in greater overstimulation and downstream adaptations like receptor desensitization that heighten psychosis susceptibility.[39] Natural cannabis users experience fewer instances of chronic affective disorders, with synthetic variants linked to higher incidences of paranoia, anxiety, and depression; one analysis found synthetic cannabinoid users reporting markedly more severe depressive symptoms than natural users.[43] The absence of an entourage effect in isolated synthetics like AM-2201 eliminates modulating terpenes and minor cannabinoids present in plant-derived products, amplifying adverse outcomes without the relative safety buffer observed in natural preparations.[44] Long-term synthetic use correlates with unpredictable metabolic byproducts contributing to nephrotoxicity and hyperemesis, effects rarer and less severe in natural cannabinoid cohorts.[42]

Detection and Analysis

Analytical Techniques

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) serves as a primary technique for detecting and quantifying AM-2201 and its metabolites in biological samples, including urine, serum, plasma, blood, and hair, with methods validated for forensic and toxicological applications using sample volumes as low as 500 μL and achieving limits of detection (LODs) in the ng/mL range. [25] [45] [46] High-resolution mass spectrometry (HRMS), often coupled with LC, enables precise mass determination for AM-2201 and related compounds like MAM-2201 in postmortem fluids, facilitating metabolite identification through accurate mass-to-charge ratios. [47] [48] Gas chromatography-mass spectrometry (GC-MS) is employed for analyzing underivatized AM-2201 in whole blood and urine, providing electron ionization spectra for structural confirmation in driving impairment cases and seized materials. [49] [45] These methods typically involve liquid-liquid or solid-phase extraction for sample preparation to minimize matrix effects and enhance sensitivity. [36] [50] Nuclear magnetic resonance (NMR) spectroscopy, including 1H, 13C, COSY, HSQC, and HMBC experiments, supports definitive structural elucidation of AM-2201 in complex mixtures, confirming its identity as 1-(5-fluoropentyl)-3-(1-naphthoyl)indole through signal assignment. For seized herbal products, LC-MS/MS and GC-MS predominate due to their compatibility with non-biological matrices, though NMR provides orthogonal verification when purity or novel analogs are suspected. [51]

Key Metabolites and Biomarkers

AM-2201 undergoes extensive phase I metabolism primarily via cytochrome P450 enzymes, resulting in oxidative defluorination, hydroxylation, and carboxylation of the side chain and indole core. In human liver microsomes, major metabolites include N-desfluoropentyl derivatives, mono- and di-hydroxylated products, with the dihydrodiol metabolite being the most abundant.[34] These pathways often lead to defluorination, producing metabolites structurally similar to those of JWH-018, such as N-(5-hydroxypentyl)-JWH-018 and N-pentanoic acid-JWH-018, which predominate in urine due to further oxidation and conjugation.[34] [35] Specific biomarkers distinguishing AM-2201 from JWH-018 include the N-(4-hydroxypentyl)-AM-2201 and 6-indole-hydroxy-AM-2201 metabolites, detected in human urine samples following intake.[35] [34] The N-4-hydroxy metabolite arises from hydroxylation at the penultimate carbon of the fluoropentyl chain, while 6-indole hydroxylation occurs on the naphthoyl-substituted indole ring. Carboxylated forms, such as those after omega-oxidation and defluorination, provide additional long-term markers, as they exhibit higher urinary concentrations and persistence compared to the parent compound.[35] Phase II glucuronidation of these hydroxylated metabolites enhances their solubility and detection window in forensic analysis.[34] In toxicological contexts, these metabolites serve as reliable biomarkers for confirming AM-2201 exposure, particularly in urine, where parent drug levels decline rapidly. The ratio of N-(5-hydroxypentyl) to N-(4-hydroxypentyl) metabolites helps differentiate AM-2201 abuse from JWH-018, aiding in legal and clinical assessments.[35] Detection typically employs liquid chromatography-mass spectrometry, targeting these specific hydroxylated and carboxylated species for specificity over shared JWH-018-like pathways.[34]

Legal and Regulatory Status

International Controls

AM-2201, chemically 1-(5-fluoropentyl)-1H-indol-3-ylmethanone, underwent a critical review by the World Health Organization's Expert Committee on Drug Dependence (ECDD) during its 36th meeting in June 2014, prompted by evidence of its clandestine manufacture, substantial recreational use, and associated health risks including acute toxicity.[52] The ECDD concluded that AM-2201 acts as a full agonist at the CB1 cannabinoid receptor with high potency, lacks recognized medical applications, and exhibits patterns of misuse comparable to other synthetic cannabinoids, recommending its placement in Schedule II of the 1971 United Nations Convention on Psychotropic Substances.[30] In response, the United Nations Commission on Narcotic Drugs (CND) formally scheduled AM-2201 in Schedule II of the 1971 Convention in December 2015, alongside JWH-018, marking one of the first specific international controls on fluorinated naphthoylindole synthetic cannabinoids.[53] This scheduling obligates the 184 signatory states to the Convention to prohibit the production, manufacture, export, import, distribution, trade, and possession of AM-2201 for non-medical or non-scientific purposes, while permitting limited activities under license for research or legitimate uses.[54] Schedule II status reflects recognition of its dependence-producing potential and limited therapeutic value, though enforcement relies on national implementation, which varies due to the substance's emergence in novel psychoactive substance markets prior to control. Post-scheduling assessments by the United Nations Office on Drugs and Crime (UNODC) indicate a decline in reported detections of AM-2201 in some regions following 2015, attributed partly to the international control's deterrent effect on large-scale production, though underground synthesis persists due to the chemical's relative simplicity and the proliferation of structural analogs evading specific listings.[53] A 2021 UNODC analysis of new psychoactive substances noted that while AM-2201's global prevalence decreased compared to pre-control trends, challenges in international monitoring persist, as evidenced by sporadic seizures in Europe and Asia, underscoring the limitations of substance-specific scheduling against rapidly evolving designer drug variants.[53] No subsequent revisions to its international status have been proposed as of 2025, with controls integrated into broader frameworks addressing synthetic cannabinoid classes.

National Bans and Enforcement Challenges

In the United States, AM-2201 was designated a Schedule I controlled substance under the cannabimimetic agents category through the Synthetic Drug Abuse Prevention Act of 2012, which expanded prohibitions on synthetic cannabinoids exhibiting effects similar to delta-9-tetrahydrocannabinol.[55] This classification criminalized its manufacture, distribution, and possession, following its emergence in herbal products reported to the National Forensic Laboratory Information System (NFLIS) with over 14,200 encounters by 2013.[56] Several states, including Missouri, explicitly listed AM-2201 as Schedule I prior to or alongside federal action, with local bans in places like Ocean City, Maryland, targeting products containing it as early as December 2011.[57][58] In Europe, AM-2201 faced national bans in multiple countries after early detections via the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Early Warning System, with initial reports from Hungary and Latvia in 2010 and expansions to 14 additional nations by 2011.[59] Individual member states, such as those responding to health incidents, implemented controls under national drug laws, often classifying it alongside other naphthoylindoles like JWH-018; by 2011-2013, it was among the most detected synthetic cannabinoids in forensic samples across the region.[25] The compound's international scheduling under Schedule II of the 1971 Convention on Psychotropic Substances, decided by the UN Commission on Narcotic Drugs on March 13, 2015, further prompted harmonized national prohibitions.[55] Enforcement challenges stem from producers' rapid structural modifications to create unregulated analogs, evading specific bans and requiring ongoing legislative amendments—a pattern observed after AM-2201's rise following JWH-018's 2011 temporary scheduling.[60] International supply chains, particularly from China, facilitate importation, as evidenced by federal prosecutions of suppliers shifting from banned precursors to AM-2201 and similar compounds.[60] Products are frequently mislabeled as "not for human consumption" or incense to exploit loopholes in analog enforcement, though U.S. Federal Analogue Act prosecutions succeed when substantial similarity and consumption intent are demonstrated; detection lags due to evolving chemistry outpacing analytical capabilities in routine policing.[61] These dynamics result in persistent underground availability despite bans, with health incidents continuing as variants proliferate.[62]

Research Applications and Controversies

Scientific Uses in Cannabinoid Studies

AM-2201, a synthetic indole-based cannabinoid, serves as a reference compound in pharmacological investigations of CB1 receptor activation due to its high binding affinity (Ki ≈ 1.0 nM) and full agonist efficacy, surpassing that of Δ9-tetrahydrocannabinol (THC) in certain assays.[63] In drug discrimination studies with rodents trained to recognize THC cues, AM-2201 fully substitutes for THC at doses as low as 0.1–0.3 mg/kg, demonstrating shared discriminative stimulus effects mediated by CB1 receptors, as these are antagonized by rimonabant.[17] Such paradigms have facilitated comparisons of structural analogs, revealing how side-chain modifications influence THC-like behavioral profiles without altering core receptor agonism.[17] In vivo pharmacodynamic evaluations have utilized AM-2201 to model cannabinoid-induced effects, including dose-dependent hypothermia (peaking at 2 hours post-administration and persisting up to 8 hours in rats at 1–10 mg/kg) and catalepsy, which correlate linearly with plasma concentrations and provide benchmarks for assessing agonist potency relative to natural cannabinoids.[16] These studies, often employing telemetry or observational scoring, underscore AM-2201's utility in dissecting CB1-driven tetrad behaviors (hypothermia, catalepsy, analgesia, reduced locomotion), though its supraphysiological efficacy raises questions about translational relevance to endogenous signaling.[64] Complementary in vitro work, including β-arrestin recruitment and ERK phosphorylation assays, positions AM-2201 as a "super-agonist" with Emax values exceeding CP55940, aiding functional selectivity analyses across G-protein versus non-G-protein pathways.[65][66] Beyond receptor pharmacology, AM-2201 has informed structure-activity relationship (SAR) explorations within naphthoylindole series, where its fluoropentyl chain enhances lipophilicity and CB1 affinity compared to non-fluorinated homologs, guiding synthesis of variants for probing steric and electronic influences on binding and efficacy.[67] Metabolic studies have leveraged AM-2201 to identify cytochrome P450 inhibition profiles, revealing potent suppression of CYP2C9 (IC50 ≈ 0.47 μM) and UGTs, which informs potential drug-drug interactions in cannabinoid research.[4] Off-target screening has further highlighted its interactions with non-CB receptors, such as GPR55, emphasizing the need for selectivity in interpreting CB1-specific outcomes.[68] Despite these applications, its recreational misuse has shifted some research toward toxicity mitigation, yet it remains a staple for elucidating synthetic cannabinoid mechanisms absent in plant-derived analogs.[25]

Debates on Prohibition Efficacy and Harm Reduction

Proponents of prohibiting AM-2201 and similar synthetic cannabinoids argue that such measures are essential to mitigate severe public health risks, including acute toxicities like psychosis, seizures, and cardiovascular events, which exceed those associated with natural cannabis.[69] For instance, AM-2201 has been linked to hospitalizations for impaired driving and metabolic disruptions in cytochrome P450 enzymes, prompting its scheduling under international controls by 2011 in multiple countries due to high abuse potential and dependence liability tied to its metabolites.[27] [26] Empirical data from emergency department visits show synthetic cannabinoids, including analogs like AM-2201, correlate with life-threatening outcomes not typical of Δ9-THC, justifying bans to limit availability and reduce incidence rates.[70] Critics contend that prohibition has limited efficacy, often resembling a "whack-a-mole" dynamic where banning specific compounds like AM-2201—prevalent in 70% of tested products post-initial bans—prompts chemists to produce structural analogs evading legal definitions, sustaining or escalating market harms.[23] [71] The UK's 2016 Psychoactive Substances Act, for example, failed to curb synthetic cannabinoid use in prisons and may have amplified individual and societal risks by driving production underground without addressing demand.[72] Similarly, U.S. federal scheduling of AM-2201 and related substances has not eradicated supply, as overseas synthesis adapts rapidly, potentially introducing untested variants with unpredictable potency.[73] Harm reduction advocates propose alternatives emphasizing public health over criminalization, arguing prohibition exacerbates dangers by fostering illicit, adulterated products while synthetic cannabinoid use partly stems from cannabis restrictions.[74] User-level strategies include "start low, go slow" dosing to avert overdose, alongside community testing for adulteration, as synthetic cannabinoids like AM-2201 pose higher risks when mixed unknowingly.[75] [76] Policy-oriented harm reduction, such as regulated cannabis access, could diminish synthetic appeal by offering safer alternatives, with evidence indicating synthetic demand persists amid prohibition failures.[71] [77] Experimental approaches like broad-spectrum vaccines aim to neutralize multiple agonists, though these remain preclinical.[78] Overall, while bans provide short-term deterrence, data suggest they inadequately suppress use or innovation, underscoring debates favoring integrated harm reduction to prioritize empirical risk mitigation.[79]

References

  1. AM 2201 | C24H22FNO | CID 53393997 - PubChem - NIH
  2. AM2201 | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
  3. Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the ...
  4. AM-2201 Inhibits Multiple Cytochrome P450 and Uridine 5 - MDPI
  5. Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and ...
  6. Fatal case of psychiatric complications following AM-2201 exposure
  7. Temporary Placement of Four Synthetic Cannabinoids Into Schedule I
  8. A new challenge in forensic toxicology exemplified by a case of ...
  9. https://www.caymanchem.com/product/27043/am2201-%28crm%29
  10. https://www.caymanchem.com/product/10707/am2201
  11. [PDF] AM-2201 - Legal High Inhaltsstoffe.de
  12. AM-2201 | Open Source Chemistry
  13. [PDF] JWH-018 and JWH-022 as Combustion Products of AM2201
  14. Synthetic Cannabinoids: Epidemiology, Pharmacodynamics, and ...
  15. AM2201 | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
  16. Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the ...
  17. Δ9-Tetrahydrocannabinol discriminative stimulus effects of AM2201 ...
  18. Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the ...
  19. The K2/Spice Phenomenon - PubMed Central - NIH
  20. Synthetic Cannabinoids | myadlm.org
  21. Synthetic cannabinoids in Europe | www.euda.europa.eu
  22. [PDF] I-TREND Substance briefing: AM-2201 - OFDT
  23. Analysis of First and Second Generation Legal Highs for Synthetic ...
  24. Synthetic Pot: Not Your Grandfather's Marijuana - PMC
  25. 1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 ... - NIH
  26. [PDF] Expert peer review No.1 Agenda item 4.7: AM-2201
  27. Analysis of AM-2201 and metabolites in a drugs and driving case
  28. [PDF] AM-2201 monograph - Soft-Tox.org
  29. Effects of bioisosteric fluorine in synthetic cannabinoid designer ...
  30. AM-2201 - Expert Committee on Drug Dependence Information ...
  31. Synthetic cannabinoid AM2201 induces seizures - PubMed
  32. Log D7.4 and plasma protein binding of synthetic cannabinoid ...
  33. Pharmacological and Toxicological Effects of Synthetic ... - NIH
  34. New Synthetic Cannabinoids Metabolism and Strategies to Best ...
  35. Determination of AM-2201 metabolites in urine and comparison with ...
  36. Determination of AM-2201 metabolites in urine and ... - PubMed
  37. Acute intoxication by synthetic cannabinoids – Four case reports
  38. [PDF] A fatal case involving several synthetic cannabinoids - gtfch.org
  39. The synthetic cannabinoids menace: a review of health risks and ...
  40. Impact of At Least 2 Years of Synthetic Cannabinoid Use on ...
  41. [PDF] Synthetic Cannabis: Toxicological Considerations
  42. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse ...
  43. Cannabinoid Use and Depression: Comparison of Natural and ...
  44. Synthetic cannabis: A comparison of patterns of use and effect ...
  45. Analysis of AM‐2201 and metabolites in a drugs and driving case
  46. Validation of an UPLC-MS/MS method for the determination of ...
  47. High-resolution mass spectrometric determination of the ... - PubMed
  48. High-resolution mass spectrometric determination of the synthetic ...
  49. GC-MS analysis of underivatised new psychoactive substances in ...
  50. Detection of urinary metabolites of AM‐2201 and UR‐144, two novel ...
  51. [PDF] Recommended Methods for the Identification and Analysis of ...
  52. [PDF] WHO Expert Committee on Drug Dependence : thirty-sixth report
  53. [PDF] Regional diversity and the impact of scheduling on NPS trends
  54. Substance Details AM-2201
  55. Definition of “Cannabimimetic Agents” and Assignment of an ...
  56. [PDF] STATEMENT OF JOSEPH T. RANNAZZISI DEPUTY ASSISTANT ...
  57. [PDF] Synthetic Cannabinoids and Synthetic Stimulants
  58. [PDF] Special Documents - Maryland Department of Health
  59. [PDF] GLOBAL SMART UPDATE - United Nations Office on Drugs and Crime
  60. Chinese chemical engineer sentenced for synthetic drugs - ICE
  61. Synthetic Cannabinoid and Mitragynine Exposure of Law ... - NIH
  62. The Synthetic Cannabinoid Chemical Arms Race and Its Effect on ...
  63. AM-2201 - an overview | ScienceDirect Topics
  64. Effects of cannabinoid agonists and antagonists in male rats ...
  65. Subtle Structural Modification of a Synthetic Cannabinoid Receptor ...
  66. In vitro determination of the efficacy of illicit synthetic cannabinoids ...
  67. Relationship between chemical structure and in vivo activity of ...
  68. Off-target pharmacological profiling of synthetic cannabinoid ...
  69. The adverse health effects of synthetic cannabinoids with emphasis ...
  70. Synthetic Cannabinoids | National Institute on Drug Abuse - NIDA
  71. Synthetic Cannabinoids Highlight the Need to Abandon the War on ...
  72. The impact of the 2016 Psychoactive Substances Act on synthetic ...
  73. Chemists Outrun Laws in War on Synthetic Drugs - WIRED
  74. [PDF] Public Comment on Synthetic Cathinones, Tetrahydrocannabinol ...
  75. Synthetic cannabinoids - Alcohol and Drug Foundation
  76. Activity-based detection of synthetic cannabinoid receptor agonists ...
  77. [PDF] FACTS ABOUT SYNTHETIC CANNABINOID | Drug Policy Alliance
  78. Broadly Neutralizing Synthetic Cannabinoid Vaccines | JACS Au
  79. The regulatory challenge of synthetic cannabinoids | Transform
User Avatar
No comments yet.